{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:34:54Z","timestamp":1771306494236,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Stefan-Morsch-Stiftung, Birkenfeld, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00432-017-2369-7","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T15:11:38Z","timestamp":1488553898000},"page":"1281-1292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"143","author":[{"given":"Michaela","family":"D\u00f6ring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Melanie","family":"Cabanillas Stanchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Queudeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Blaeschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schlegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Handgretinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner J.","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"2369_CR1","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1086\/313445","volume":"29","author":"S Abbasi","year":"1999","unstructured":"Abbasi S, Shenep JL, Hughes WT, Flynn PM (1999) Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 29:1210\u20131219. doi:\n10.1086\/313445","journal-title":"Clin Infect Dis"},{"key":"2369_CR2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/jac\/48.6.769","volume":"48","author":"F Barchiesi","year":"2001","unstructured":"Barchiesi F, Schimizzi AM, Caselli F, Giannini D, Camiletti V, Fileni B, Giacometti A, Di Francesco LF, Scalise G (2001) Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 48:769\u2013773","journal-title":"J Antimicrob Chemother"},{"key":"2369_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bmcl.2005.09.031","volume":"16","author":"F Bennett","year":"2006","unstructured":"Bennett F, Saksena AK, Lovey RG et al. (2006) Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S, S)-5] Bioorg Med Chem Lett 16:186\u2013190 doi:\n10.1016\/j.bmcl.2005.09.031","journal-title":"Bioorg Med Chem Lett"},{"key":"2369_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1345\/aph.1R775","volume":"47","author":"VA Bernardo","year":"2013","unstructured":"Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL (2013) Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 47:976\u2013983. doi:\n10.1345\/aph.1R775","journal-title":"Ann Pharmacother"},{"key":"2369_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/01.inf.0000220256.69385.2e","volume":"25","author":"E Castagnola","year":"2006","unstructured":"Castagnola E, Cesaro S, Giacchino M et al (2006) Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 25:634\u2013639. doi:\n10.1097\/01.inf.0000220256.69385.2e","journal-title":"Pediatr Infect Dis J"},{"key":"2369_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10096-010-1123-8","volume":"30","author":"S Cesaro","year":"2011","unstructured":"Cesaro S, Milano GM, Aversa F (2011) Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis 30:595\u2013596. doi:\n10.1007\/s10096-010-1123-8","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2369_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348\u2013359. doi:\n10.1056\/NEJMoa061094","journal-title":"N Engl J Med"},{"key":"2369_CR8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","volume":"47","author":"R Courtney","year":"2003","unstructured":"Courtney R, Pai S, Laughlin M, Lim J, Batra V (2003) Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47:2788\u20132795","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis 46:1813\u20131821. doi:\n10.1086\/588660","journal-title":"Clin Infect Dis"},{"key":"2369_CR10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF02471906","volume":"16","author":"DW Denning","year":"1997","unstructured":"Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE (1997) Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Br Soc Med Mycol Eur J Clin Microbiol Infect Dis 16:424\u2013436","journal-title":"Br Soc Med Mycol Eur J Clin Microbiol Infect Dis"},{"key":"2369_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2334-12-263","volume":"12","author":"M D\u00f6ring","year":"2012","unstructured":"D\u00f6ring M, M\u00fcller C, Johann PD, Erbacher A, Kimmig A, Schwarze CP, Lang P, Handgretinger R, M\u00fcller I (2012) Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 12:263. doi:\n10.1186\/1471-2334-12-263","journal-title":"BMC Infect Dis"},{"key":"2369_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10096-013-1998-2","volume":"33","author":"M D\u00f6ring","year":"2014","unstructured":"D\u00f6ring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze CP, Lang P, Handgretinger R, M\u00fcller I (2014) Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 33:629\u2013638. doi:\n10.1007\/s10096-013-1998-2","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2369_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/INF.0b013e3181b076b1","volume":"28","author":"HJ Dornbusch","year":"2009","unstructured":"Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH (2009) Invasive fungal infections in children. Pediatr Infect Dis J 28:734\u2013737. doi:\n10.1097\/INF.0b013e3181b076b1","journal-title":"Pediatr Infect Dis J"},{"key":"2369_CR14","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/aac.03050-14","volume":"58","author":"RF Duarte","year":"2014","unstructured":"Duarte RF, Lopez-Jimenez J, Cornely OA et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58:5758\u20135765. doi:\n10.1128\/aac.03050-14","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR15","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1128\/aac.00496-15","volume":"59","author":"U Durani","year":"2015","unstructured":"Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ (2015) Retrospective comparison of posaconazole levels in patients taking the delayed-release tablet versus the oral suspension. Antimicrob Agents Chemother 59:4914\u20134918. doi:\n10.1128\/aac.00496-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00148581-200810050-00003","volume":"10","author":"BT Fisher","year":"2008","unstructured":"Fisher BT, Zaoutis TE (2008) Treatment of invasive candidiasis in immunocompromised pediatric patients. Paediatr Drugs 10:281\u2013298","journal-title":"Paediatr Drugs"},{"key":"2369_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1586\/14787210.3.4.467","volume":"3","author":"AH Groll","year":"2005","unstructured":"Groll AH, Walsh TJ (2005) Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 3:467\u2013487. doi:\n10.1586\/14787210.3.4.467","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"2369_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1439-0507.2006.01296.x","volume":"49","author":"AH Groll","year":"2006","unstructured":"Groll AH, Walsh TJ (2006) Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 49(Suppl 1):7\u201316. doi:\n10.1111\/j.1439-0507.2006.01296.x","journal-title":"Mycoses"},{"key":"2369_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","volume":"33","author":"AH Groll","year":"1996","unstructured":"Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33:23\u201332","journal-title":"J Infect"},{"key":"2369_CR20","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/s1470-2045(14)70017-8","volume":"15","author":"AH Groll","year":"2014","unstructured":"Groll AH, Castagnola E, Cesaro S et al (2014) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327\u2013e340. doi:\n10.1016\/s1470-2045(14)70017-8","journal-title":"Lancet Oncol"},{"key":"2369_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/phar.1533","volume":"35","author":"AJ Guarascio","year":"2015","unstructured":"Guarascio AJ, Slain D (2015) Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. Pharmacotherapy 35:208\u2013219. doi:\n10.1002\/phar.1533","journal-title":"Pharmacotherapy"},{"key":"2369_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2141.2009.08072.x","volume":"149","author":"KA Hale","year":"2010","unstructured":"Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC (2010) Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol 149:263\u2013272. doi:\n10.1111\/j.1365-2141.2009.08072.x","journal-title":"Br J Haematol"},{"key":"2369_CR23","unstructured":"Institute USDOHAHSNIoHNC (2009) Common Terminology Criteria for Adverse Events v4.03 (CTCAE). U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute"},{"key":"2369_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.2010.64","volume":"88","author":"SH Jang","year":"2010","unstructured":"Jang SH, Colangelo PM, Gobburu JV (2010) Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 88:115\u2013119. doi:\n10.1038\/clpt.2010.64","journal-title":"Clin Pharmacol Ther"},{"key":"2369_CR25","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1128\/aac.00213-09","volume":"53","author":"K Kahle","year":"2009","unstructured":"Kahle K, Langmann P, Schirmer D, Lenker U, Keller D, Helle A, Klinker H, Heinz WJ (2009) Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother 53:3140\u20133142. doi:\n10.1128\/aac.00213-09","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR26","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1128\/aac.05000-14","volume":"59","author":"WM Kersemaekers","year":"2015","unstructured":"Kersemaekers WM, Dogterom P, Xu J, Marcantonio EE, de Greef R, Waskin H, van Iersel ML (2015) Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother 59:3385\u20133389. doi:\n10.1128\/aac.05000-14","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR27","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1128\/aac.02448-13","volume":"58","author":"WK Kraft","year":"2014","unstructured":"Kraft WK, Chang PS, van Iersel ML, Waskin H, Krishna G, Kersemaekers WM (2014) Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 58:4020\u20134025. doi:\n10.1128\/aac.02448-13","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1592\/phco","volume":"27","author":"G Krishna","year":"2007","unstructured":"Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H (2007a) Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:12. doi:\n10.1592\/phco.16270","journal-title":"Pharmacotherapy"},{"key":"2369_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1128\/aac.00454-06","volume":"51","author":"G Krishna","year":"2007","unstructured":"Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L (2007b) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 51:812\u2013818. doi:\n10.1128\/aac.00454-06","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","volume":"28","author":"G Krishna","year":"2008","unstructured":"Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA (2008) Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223\u20131232. doi:\n10.1592\/phco.28.10.1223","journal-title":"Pharmacotherapy"},{"key":"2369_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1128\/aac.01034-08","volume":"53","author":"G Krishna","year":"2009","unstructured":"Krishna G, Moton A, Ma L, Medlock MM, McLeod J (2009) Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958\u2013966. doi:\n10.1128\/aac.01034-08","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR32","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1128\/aac.00222-12","volume":"56","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, O\u2019Mara E (2012a) Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 56:4196\u20134201. doi:\n10.1128\/aac.00222-12","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR33","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1093\/jac\/dks268","volume":"67","author":"G Krishna","year":"2012","unstructured":"Krishna G, Ma L, Martinho M, Preston RA, O\u2019Mara E (2012b) A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 67:2725\u20132730. doi:\n10.1093\/jac\/dks268","journal-title":"J Antimicrob Chemother"},{"key":"2369_CR34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1439-0507.2009.01691.x","volume":"52","author":"C Lass-Fl\u00f6rl","year":"2009","unstructured":"Lass-Fl\u00f6rl C (2009) The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52:197\u2013205","journal-title":"Mycoses"},{"key":"2369_CR35","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10096-010-0957-4","volume":"29","author":"T Lehrnbecher","year":"2010","unstructured":"Lehrnbecher T, Attarbaschi A, Duerken M et al (2010a) Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis 29:1043\u20131045. doi:\n10.1007\/s10096-010-0957-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2369_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jinf.2010.06.018","volume":"61","author":"T Lehrnbecher","year":"2010","unstructured":"Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D (2010b) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 61:259\u2013265. doi:\n10.1016\/j.jinf.2010.06.018","journal-title":"J Infect"},{"key":"2369_CR37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/318483","volume":"32","author":"SJ Lin","year":"2001","unstructured":"Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358\u2013366. doi:\n10.1086\/318483","journal-title":"Clin Infect Dis"},{"key":"2369_CR38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1365-2354.2001.00241.x","volume":"10","author":"J Maertens","year":"2001","unstructured":"Maertens J, Vrebos M, Boogaerts M (2001) Assessing risk factors for systemic fungal infections. Eur J Cancer Care (Engl) 10:56\u201362","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2369_CR39","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2165\/00003495-200767130-00001","volume":"67","author":"AN Malani","year":"2007","unstructured":"Malani AN, Kauffman CA (2007) Changing epidemiology of rare mould infections: implications for therapy. Drugs 67:1803\u20131812","journal-title":"Drugs"},{"key":"2369_CR40","first-page":"10","volume":"17","author":"JD Meyers","year":"1990","unstructured":"Meyers JD (1990) Fungal infections in bone marrow transplant patients. Semin Oncol 17:10\u201313","journal-title":"Semin Oncol"},{"key":"2369_CR41","unstructured":"MSD SHARP & DOHME GMBH (09\/2013) Noxafil (R) 40\u00a0mg\/ml oral suspension-Posaconazole. Product information., Version 009310-F921 edn. MSD SHARP & DOHME GMBH"},{"key":"2369_CR42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/clind\/24.4.575","volume":"24","author":"M Nucci","year":"1997","unstructured":"Nucci M, Spector N, Bueno AP, Solza C, Perecmanis T, Bacha PC, Pulcheri W (1997) Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis 24:575\u2013579","journal-title":"Clin Infect Dis"},{"key":"2369_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1534734607313879","volume":"7","author":"A Rekha","year":"2008","unstructured":"Rekha A, Kindo AJ, Ravi A (2008) Fusarium solani in the post-transplant patient: an unusual fungus. Int J Low Extrem Wounds 7:38\u201340. doi:\n10.1177\/1534734607313879","journal-title":"Int J Low Extrem Wounds"},{"key":"2369_CR44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mph.0000155861.38641.ca","volume":"27","author":"GP Rosen","year":"2005","unstructured":"Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27:135\u2013140","journal-title":"J Pediatr Hematol Oncol"},{"key":"2369_CR45","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1128\/aac.00163-06","volume":"50","author":"F Sabatelli","year":"2006","unstructured":"Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50:2009\u20132015. doi:\n10.1128\/aac.00163-06","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR46","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1128\/aac.01489-12","volume":"56","author":"I Sanchez-Ortega","year":"2012","unstructured":"Sanchez-Ortega I, Vazquez L, Montes C, Patino B, Arnan M, Bermudez A, Yanez L, Caballero T, Duarte RF (2012) Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrob Agents Chemother 56:6422\u20136424. doi:\n10.1128\/aac.01489-12","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR47","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s00432-015-1962-x","volume":"141","author":"KG Schrenk","year":"2015","unstructured":"Schrenk KG, Schnetzke U, Stegemann K, von Lilienfeld-Toal M, Hochhaus A, Scholl S (2015) Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia. J Cancer Res Clin Oncol 141:1661\u20131668. doi:\n10.1007\/s00432-015-1962-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"2369_CR48","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","volume":"46","author":"QN Sun","year":"2002","unstructured":"Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46:1581\u20131582","journal-title":"Antimicrob Agents Chemother"},{"key":"2369_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335\u2013347. doi:\n10.1056\/NEJMoa061098","journal-title":"N Engl J Med"},{"key":"2369_CR50","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1185\/03007995.2010.487796","volume":"26","author":"T Zaoutis","year":"2010","unstructured":"Zaoutis T (2010) Candidemia in children. Curr Med Res Opin 26:1761\u20131768. doi:\n10.1185\/03007995.2010.487796","journal-title":"Curr Med Res Opin"},{"key":"2369_CR51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.inf.0000128781.77600.6f","volume":"23","author":"TE Zaoutis","year":"2004","unstructured":"Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE (2004) Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 23:635\u2013641","journal-title":"Pediatr Infect Dis J"},{"key":"2369_CR52","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1542\/peds.2005-1161","volume":"117","author":"TE Zaoutis","year":"2006","unstructured":"Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ (2006) Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711\u2013e716. doi:\n10.1542\/peds.2005-1161","journal-title":"Pediatrics"},{"key":"2369_CR53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/00015458.2005.11681154","volume":"105","author":"C Zirak","year":"2005","unstructured":"Zirak C, Brutus JP, De Mey A (2005) Atypical cause of forearm skin ulceration in a leukaemic child: mucormycosis. A case report. Acta Chir Belg 105:551\u2013553","journal-title":"Acta Chir Belg"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2369-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2369-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T14:35:28Z","timestamp":1498142128000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2369-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2369-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}